N-terminal modification is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Preclinical === EB-002 (EB-373; psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen [16] Midomafetamine (MDMA; ecstasy) microneedle patch – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [17] Nerinetide (NA-1; Tat-NR2B9c) – PDZ domain inhibitor [18] OV-4041 – potassium–chloride-cotransporter agonist [19] PSIL-025 – serotonin 5-HT1 receptor modulator [20]
== Gene expression assays == Reporter genes can be used to assay for the expression of a gene of interest that is normally difficult to quantitatively assay. Reporter genes can produce a protein that has little obvious or immediate effect on the cell culture or organism. They are ideally not present in the native genome to be able to isolate reporter gene expression as a result of the gene of interest's expression. To activate reporter genes, they can be expressed constitutively, where they are directly attached to the gene of interest to create a gene fusion. This method is an example of using cis-acting elements where the two genes are under the same promoter elements and are transcribed into a single messenger RNA molecule. The mRNA is then translated into protein. It is important that both proteins be able to properly fold into their active conformations and interact with their substrates despite being fused. In building the DNA construct, a segment of DNA coding for a flexible polypeptide linker region is usually included so that the reporter and the gene product will only minimally interfere with one another. Reporter genes can also be expressed by induction during growth. In these cases, trans-acting elements, such as transcription factors are used to express the reporter gene. Reporter gene assay have been increasingly used in high throughput screening (HTS) to identify small molecule inhibitors and activators of protein targets and pathways for drug discovery and chemical biology. Because the reporter enzymes themselves (e.g.
== Subsidiaries == OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
Sources: en.wikipedia.org
=== D11AH Agents for dermatitis, excluding corticosteroids === D11AH01 Tacrolimus D11AH02 Pimecrolimus D11AH03 Cromoglicic acid D11AH04 Alitretinoin D11AH05 Dupilumab D11AH06 Crisaborole D11AH07 Tralokinumab D11AH08 Abrocitinib D11AH09 Ruxolitinib D11AH10 Lebrikizumab D11AH11 Delgocitinib D11AH12 Nemolizumab QD11AH90 Oclacitinib QD11AH91 Lokivetmab QD11AH92 Ilunocitinib QD11AH93 Atinvicitinib
=== Mitral regurgitation === Patients with mitral regurgitation may present with heart failure symptoms, such as dyspnea on exertion, orthopnea and paroxysmal nocturnal dyspnea, palpitations, or pulmonary edema. On auscultation of a patient with mitral stenosis, there may be a holosystolic murmur at the apex, radiating to the back or clavicular area, a third heart sound, and a loud, palpable P2, heard best when lying on the left side. Patients also commonly have atrial fibrillation. Patients may have a laterally displaced apex beat, often with heave In acute cases, the murmur and tachycardia may be only distinctive signs.
== History == It was first used in 1795 shortly after the formation of the Orange Order and was the original system put together by the founding members of the Orange Order. The Grand Orange Lodge of Ireland disliked the ritualism and tried to suppress it as early as 1798 however, the main reason for the opposition to the Royal Arch Purple Degree was that many rural Lodges were practising other degrees in addition to the Royal Arch Purple degree and the gentry deemed this as unacceptable and realised the need for a central system of degrees. The Royal Arch Purple degree was practised in secrecy for a period after the Grand Lodge (in Dublin) deemed the degree illegal, however it was kept alive by the Lodges around County Armagh as it was the system of 'travel' closest to the original ritual put together by the founding members of the Orange Order in 1795. The Grand Lodge maintains their position in not recognising the degree to this day although it now, rather grudgingly, recognises the Royal Arch Purple as an official Order. It was re-constituted in 1911, with the explicit intentions of promoting the Reformed Faith, Charity amongst all men and maintaining historic Orangeism. It was granted its Royal title by the Duke of Cumberland, King Ernest Augustus of Hanover, who was the fifth son of King George III, and brother to King George IV and King William IV, whom he succeeded as King of Hanover.
Sources: en.wikipedia.org
=== Theatre === Doillon, alongside director Michel Didym, created a show based on letters written by French authors and singers (Louis-Ferdinand Celine, Marcel Proust and Édith Piaf), and monologues. She toured French-speaking theatres throughout Europe by herself for over two years. In 2010, Doillon started working with director Arthur Nauzyciel on Samuel Beckett's one sentence monologue "L'Image" in the National Theatre of Orléans. Alongside dancer Damien Jalet and conceptual musician Meelice, they performed throughout France and in New York for the Crossing the Line Festival. In 2017, for the National Theatre of Rennes, Doillon performed "L'Image" directed by Nauzyciel for a week. Doillon has also collaborated on various performances (Paroles d'Exil/Musique Interdite with the French National Orchestra, Calamity Jane with singer/ musician John Mitchell and as a reader for many French-literature festivals).
=== Requirements === The Food and Nutrition Board of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For methionine combined with cysteine, for adults 19 years and older, 19 mg/kg body weight/day. This translates to about 1.33 grams per day for a 70 kilogram individual.
UbiPred is a SVM-based prediction server using 31 physicochemical properties for predicting ubiquitylation sites. UbPred is a random forest-based predictor of potential ubiquitination sites in proteins. It was trained on a combined set of 266 non-redundant experimentally verified ubiquitination sites available from our experiments and from two large-scale proteomics studies. CKSAAP_UbSite is SVM-based prediction that employs the composition of k-spaced amino acid pairs surrounding a query site (i.e. any lysine in a query sequence) as input, uses the same dataset as UbPred.
The first island chain is the first string of major Pacific archipelagos out from the East Asian continental mainland coast. It is principally composed of the Kuril Islands, the Japanese archipelago, the Ryukyu Islands, Taiwan (Formosa), the northern Philippines, and Borneo, extending all the way from the Kamchatka Peninsula in the northeast to the Malay Peninsula in the southwest. The first island chain is one of three island chain doctrines within the island chain strategy of US foreign policy. It is considered a strategic military barrier to accessing the wider Pacific Ocean given the relative shallowness of waters to the west of the first island chain, which has important implications for submarine detection.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.